KoBioLabs, Inc Stock

Equities

A348150

KR7348150004

Food Processing

End-of-day quote Korea S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
7,730 KRW +1.31% Intraday chart for KoBioLabs, Inc +2.79% -9.17%

Financials

Sales 2022 11.61B 8.38M 11.54M Sales 2023 33.14B 23.93M 32.94M Capitalization 161B 116M 160M
Net income 2022 -21.92B -15.83M -21.79M Net income 2023 -13.85B -10M -13.77M EV / Sales 2022 9.66 x
Net cash position 2022 79.17B 57.16M 78.69M Net cash position 2023 47.95B 34.62M 47.66M EV / Sales 2023 3.4 x
P/E ratio 2022
-8.47 x
P/E ratio 2023
-11.4 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 66.03%
More Fundamentals * Assessed data
Dynamic Chart
5,607,000 Common Stock of KoBioLabs,Inc are subject to a Lock-Up Agreement Ending on 18-NOV-2022. CI
KoBioLabs, Inc announced that it has received KRW 10.000016 billion in funding from E-MART Inc. CI
KoBioLabs to Raise $8 Million via Stock Offering MT
KoBioLabs, Inc announced that it expects to receive KRW 10.000016 billion in funding from E-MART Inc. CI
KoBioLabs, Inc announced that it has received KRW 6.99999775 billion in funding from Stonebridge Ventures Inc., Industrial Bank of Korea, Investment Arm and other investors CI
KoBioLabs, Inc announced that it has received KRW 4.64999775 billion in funding CI
KoBioLabs, Inc announced that it expects to receive KRW 6.99999775 billion in funding from Stonebridge Ventures Inc., Industrial Bank of Korea, Investment Arm and other investors CI
KoBioLabs, Inc announced that it has received KRW 44.4498035 billion in funding from Jaedam Inc., Cornerstone Investment Partners Co., Ltd. and other investors CI
1,130,196 Common Stock of KoBioLabs,Inc are subject to a Lock-Up Agreement Ending on 18-NOV-2021. CI
Kobiolabs Targets Over $28 Million Through Stock Offering MT
KoBioLabs, Inc announced that it expects to receive KRW 44.4498035 billion in funding from Jaedam Inc., Cornerstone Investment Partners Co., Ltd. and other investors CI
KoBioLabs, Inc(KOSDAQ:A348150) added to S&P Global BMI Index CI
213,600 Common Stock of KoBioLabs,Inc are subject to a Lock-Up Agreement Ending on 18-MAY-2021. CI
840,158 Common Stock of KoBioLabs,Inc are subject to a Lock-Up Agreement Ending on 18-FEB-2021. CI
845,970 Common Stock of KoBioLabs,Inc are subject to a Lock-Up Agreement Ending on 18-JAN-2021. CI
More news
1 day+1.31%
1 week+2.79%
Current month-8.52%
1 month-8.52%
3 months-23.39%
6 months+8.42%
Current year-9.17%
More quotes
1 week
7 370.00
Extreme 7370
7 750.00
1 month
7 140.00
Extreme 7140
8 700.00
Current year
7 140.00
Extreme 7140
14 150.00
1 year
6 990.00
Extreme 6990
14 150.00
3 years
6 990.00
Extreme 6990
37 750.00
5 years
6 990.00
Extreme 6990
68 600.00
10 years
6 990.00
Extreme 6990
68 600.00
More quotes
Managers TitleAgeSince
Founder 54 14-08-10
Director of Finance/CFO - 22-12-31
Chief Operating Officer - 22-12-31
Members of the board TitleAgeSince
Founder 54 14-08-10
Director/Board Member 55 -
More insiders
Date Price Change Volume
24-04-30 7,730 +1.31% 40,613
24-04-29 7,630 +2.14% 32,291
24-04-26 7,470 -0.66% 30,064
24-04-25 7,520 -1.70% 23,637
24-04-24 7,650 +0.66% 29,607

End-of-day quote Korea S.E., April 29, 2024

More quotes
KoBioLabs Inc is a Korea-based company mainly engaged in the development and sales of functional probiotics. The Company's products are sold under the names of Bioviom and Queens henna FOODOLOGY. The Company is also engaged in the development of new microbiome drugs. In addition, the Company engages in commissioned research. The Company sells its products in domestic and overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. A348150 Stock